List of Excipients in Branded Drug OPVEE

OPVEE Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

OPVEE is Indivior’s nalmefene hydrochloride nasal spray for emergency treatment of opioid overdose. Its commercial formulation uses a conventional aqueous nasal-spray platform: a buffered, isotonic solution with antimicrobial preservation and chelation. The main excipient opportunity is not a simple substitution of one inactive ingredient. It is the development of preservative-free, multidose, device-compatible, pediatric-friendly, and improved-shelf-life presentations that maintain rapid nalmefene absorption and reliable administration during overdose events.

What is OPVEE and how does its formulation work?

OPVEE contains 2.7 mg of nalmefene hydrochloride per 0.1 mL nasal spray. It is supplied as a single-dose, ready-to-use device for emergency reversal of opioid overdose in adults and pediatric patients age 12 years and older who weigh at least 40 kg.[1]

Attribute	OPVEE profile
Active ingredient	Nalmefene hydrochloride
Dosage form	Nasal spray
Strength	2.7 mg per 0.1 mL
Route	Intranasal
Sponsor	Indivior Inc.
FDA application	NDA 215457
FDA approval	May 22, 2023
Primary use	Emergency treatment of opioid overdose
Administration	One spray in one nostril; repeat dosing may be required
Commercial format	Single-dose nasal-spray device

Nalmefene is a long-acting opioid receptor antagonist. The product competes directly with naloxone products, particularly Narcan nasal spray and generic naloxone nasal sprays. OPVEE’s commercial rationale is based on nalmefene’s pharmacology, including its longer duration of opioid receptor antagonism, rather than on a novel excipient system.

What excipients are used in OPVEE?

OPVEE uses a relatively standard nasal aqueous formulation. The FDA prescribing information identifies the following inactive ingredients:

Excipient or component	Likely formulation function
Benzalkonium chloride	Antimicrobial preservative
Disodium edetate	Chelating agent; supports preservative performance and chemical stability
Sodium citrate dihydrate	Buffer component
Citric acid monohydrate	Buffer and pH adjustment
Sodium chloride	Tonicity adjustment
Hydrochloric acid	pH adjustment
Sodium hydroxide	pH adjustment
Water for injection	Vehicle

The formulation is designed to balance four technical requirements:

1. Keep nalmefene hydrochloride dissolved.
2. Maintain a nasal-compatible pH and osmolality.
3. Protect the solution from microbial contamination.
4. Deliver a reproducible dose through a single-use nasal device.

The presence of benzalkonium chloride and disodium edetate indicates that the formulation relies on a preserved aqueous platform. The buffer system uses citric acid and sodium citrate. Sodium chloride adjusts tonicity, while hydrochloric acid and sodium hydroxide permit final pH control during manufacturing.[1]

Which excipients create the greatest commercial opportunity?

The largest commercial opportunities are in preservative-free systems, multidose preservation, mucoadhesive delivery, device compatibility, and stability enhancement.

Preservative-free nasal spray systems

Benzalkonium chloride is effective and widely used, but its repeated-use profile can create tolerability and regulatory concerns in chronic intranasal therapies. OPVEE is an emergency product intended for intermittent use, so the risk-benefit analysis differs from that of daily nasal medicines. Even so, a preservative-free presentation could offer a differentiated product for:

• Public-health agencies purchasing large inventories.
• School systems and universities.
• Emergency medical services.
• Correctional facilities.
• Hospitals and pharmacies seeking broad nasal tolerability.
• Patients requiring repeated or multiple doses during a single overdose event.

Potential preservative-free approaches include unit-dose packaging, sterile blow-fill-seal containers, single-dose ampoules coupled to a nasal actuator, and device designs that prevent back-contamination.

The commercial barrier is cost. A preservative-free system may require more complex sterile manufacturing, higher container-closure controls, and more demanding microbial validation. For a low-frequency emergency product, the added cost must be justified by procurement preferences, tolerability data, or a clearly improved shelf-life profile.

Alternative antimicrobial systems

A reformulated product could evaluate preservatives such as phenoxyethanol, chlorobutanol, potassium sorbate, or other nasal-compatible antimicrobial systems. Direct substitution would not be sufficient. Each candidate must be assessed for:

• Nalmefene chemical stability.
• Nasal irritation.
• Preservative effectiveness.
• Compatibility with the pump, elastomers, and container.
• Extractables and leachables.
• Dose uniformity over the labeled shelf life.
• Impact on mucociliary clearance.

Benzalkonium chloride can interact with device materials and may alter surface properties. A replacement excipient could create commercial value if it improves tolerability without reducing microbial protection or spray performance.

Mucoadhesive excipients

Mucoadhesive polymers could increase residence time in the nasal cavity. Candidate classes include hydroxypropyl methylcellulose, hydroxypropyl cellulose, polycarbophil, carbomers, hyaluronic acid, and selected chitosan systems.

The technical objective would be to improve nasal retention without slowing systemic absorption. That is difficult for OPVEE because emergency reversal requires rapid onset. Excessive viscosity or strong mucoadhesion could reduce plume formation, impair pump performance, or delay absorption.

A commercially viable mucoadhesive formulation would need to demonstrate:

• Equivalent or faster exposure than the existing product.
• Consistent delivery across variable nasal conditions.
• Acceptable spray pattern and droplet-size distribution.
• No clinically meaningful increase in nasal irritation.
• Reliable performance during congestion, bleeding, or abnormal nasal anatomy.

Mucoadhesion is therefore more attractive for a differentiated lifecycle product than for a direct generic substitution.

How does OPVEE’s excipient strategy compare with naloxone nasal sprays?

OPVEE and naloxone nasal sprays share the same broad formulation architecture: an aqueous nasal solution delivered through a metered device. The commercial distinction is the active ingredient and dosing strategy, not a clearly superior excipient platform.

Product	Active ingredient	Typical formulation strategy	Commercial positioning
OPVEE	Nalmefene hydrochloride	Preserved, buffered, isotonic aqueous nasal spray	Longer-acting opioid antagonism
Narcan	Naloxone hydrochloride	Preserved aqueous nasal spray	Established emergency reversal product
Generic naloxone nasal sprays	Naloxone hydrochloride	Generally similar aqueous nasal platform	Price competition and institutional access

OPVEE’s excipient system does not independently establish a strong competitive moat. The stronger product-level differentiators are:

• Nalmefene’s longer pharmacologic activity.
• The 2.7 mg nasal presentation.
• Emergency-use labeling.
• Distribution and public-sector contracting.
• Device reliability.
• Supply availability during opioid-overdose surges.

A competitor using the same active ingredient could seek a different excipient profile, but an excipient change would require evidence that the new formulation remains bioequivalent or clinically comparable and performs reliably in overdose conditions.

What formulation patents may protect OPVEE?

Formulation-related protection can cover more than the named inactive ingredients. Relevant claim categories may include:

• Concentration ranges for nalmefene hydrochloride.
• pH ranges.
• Buffer systems.
• Preservative and chelator combinations.
• Osmolality ranges.
• Nasal spray dose volume.
• Particle or droplet-size distribution.
• Device and formulation combinations.
• Storage stability.
• Methods of treating opioid overdose using the formulation.

The presence of benzalkonium chloride, citrate, sodium chloride, or disodium edetate in the FDA label does not establish that each ingredient is independently patented. Patent strength depends on the claim language, priority date, written description, prosecution history, patent term, and whether the claim requires a specific combination or numerical range.

For a competing product, the principal design-around questions are:

1. Can the product remove benzalkonium chloride while retaining microbial control?
2. Can it use a different buffer without entering a claimed pH or concentration range?
3. Can it use a different device with the same nalmefene dose?
4. Can it maintain equivalent exposure without practicing a claimed formulation combination?
5. Can it avoid method-of-use claims covering emergency opioid reversal?

A formulation patent with narrow excipient ranges may be vulnerable to design-around. A patent covering the active ingredient, nasal delivery system, dose, and treatment method in combination may create a broader barrier.

When does OPVEE lose regulatory exclusivity?

OPVEE was approved in May 2023. Nalmefene was previously approved in injectable forms, so OPVEE’s regulatory exclusivity profile does not automatically receive the five-year new chemical entity period available to a first approval of a new active moiety.

The relevant regulatory protection is more likely to involve:

• Three-year exclusivity based on new clinical investigations essential to approval.
• Any pediatric exclusivity awarded later.
• Patent protection listed in the FDA Orange Book.
• Potential orphan-drug protection only if the product received an orphan designation and approval for a qualifying rare disease indication.

The FDA label and Drugs@FDA record establish the approval date and approved formulation. They do not, by themselves, establish the end dates of all patent rights or exclusivity periods. Market-entry analysis must separate FDA regulatory exclusivity from patent enforceability.[1,2]

What is the Orange Book and Paragraph IV risk for OPVEE?

An abbreviated new drug application applicant could challenge listed patents through a Paragraph IV certification if it asserts that the patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory conditions.[3]

Potential generic challenges could target:

• The nalmefene nasal formulation.
• The metered-dose device.
• Formulation stability.
• The combination of preservative, chelator, buffer, and active ingredient.
• Treatment methods for opioid overdose.
• Device performance claims.

The strongest generic opportunity would likely involve a product with the same nalmefene strength and nasal route but a materially different excipient system and device. The principal regulatory hurdle would be demonstrating bioequivalence and comparable nasal delivery.

The absence of a complex biologic manufacturing process makes OPVEE more accessible to generic development than a biologic or long-acting depot product. The device, formulation, and patent combination can still delay entry.

What manufacturing and IP barriers affect excipient substitution?

Excipient substitution is constrained by manufacturing and regulatory requirements.

Manufacturing barriers

A replacement formulation may require:

• New raw-material specifications.
• New supplier qualification.
• Revised mixing order and process controls.
• New sterilization or aseptic-processing validation.
• New container-closure studies.
• New extractables and leachables assessments.
• New preservative-effectiveness testing.
• New stability studies.
• New spray-content uniformity and plume testing.

A change in viscosity can affect pump priming, actuation force, delivered volume, plume geometry, and nasal deposition. A change in ionic strength can alter nalmefene solubility and preservative behavior. A change in pH can affect both chemical stability and nasal tolerability.

Intellectual-property barriers

Potentially relevant IP families may protect:

• Nalmefene nasal delivery.
• Specific aqueous compositions.
• Excipient combinations.
• Device architecture.
• Dose delivery.
• Use in opioid overdose.
• Manufacturing processes.

A company should not assume that a formulation is clear to operate because its excipients are common pharmaceutical ingredients. Patent claims can cover a combination of individually generic materials.

Which commercial opportunities exist beyond a direct generic?

The most attractive opportunities are differentiated lifecycle products rather than simple excipient copies.

Opportunity	Value proposition	Main development risk
Preservative-free unit dose	Improved tolerability and institutional appeal	Higher sterile-manufacturing cost
Multidose device	More doses per package during prolonged overdose	Contamination and dose-uniformity risk
Pediatric presentation	Broader access for younger or lower-weight patients	Dose selection and clinical evidence
Lower-cost public-sector version	Better access for agencies and harm-reduction programs	Margin compression
Heat-stable formulation	Improved stockpiling and field deployment	Long-term stability burden
Improved nasal retention	Potentially more consistent absorption	Risk of delayed onset
Alternative device	Better usability in emergency conditions	Device qualification and human factors
Combination emergency kit	Nalmefene plus rescue-use accessories	Regulatory classification and packaging complexity

A heat-stable product could have particular value because naloxone and nalmefene products are stored in vehicles, schools, public buildings, shelters, and emergency kits. A formulation that maintains specification under higher temperatures could reduce replacement costs and improve inventory reliability.

A product designed for low-resource settings would need more than a low price. It would need durable packaging, simple instructions, broad temperature tolerance, high dose reliability, and a device that works without assembly.

How strong is OPVEE’s excipient-based competitive position?

OPVEE’s excipient position is moderate, not dominant.

The formulation uses established excipients with broad pharmaceutical precedent. That lowers development risk but also limits differentiation. Common excipients are generally easier for competitors to replace than novel delivery technologies. The strongest defensibility is likely to come from the integrated product:

• Nalmefene active ingredient.
• Specific intranasal dose.
• Metered delivery device.
• Emergency-use labeling.
• Clinical and pharmacokinetic data.
• Manufacturing know-how.
• Patent and regulatory rights.

The excipient estate becomes commercially stronger if claims require a specific combination that produces an unexpected result, such as improved stability, rapid absorption, reduced irritation, or reliable delivery after prolonged storage.

What litigation and settlement issues could affect OPVEE?

Potential litigation would likely arise from a generic nasal nalmefene application or from a competitor seeking to market a similar emergency opioid-antagonist product. Key issues could include:

• Validity of formulation claims.
• Obviousness of combining known nasal excipients.
• Infringement by an alternative preservative system.
• Scope of device claims.
• Applicability of method-of-use claims.
• FDA Orange Book listing accuracy.
• Timing of Paragraph IV notices.
• 30-month stay mechanics.
• Settlement restrictions and launch dates.

No settlement should be assumed without a public court filing, FDA record, or company disclosure. For commercial planning, a launch model should include at least three scenarios: patent-protected launch delay, authorized generic entry, and at-risk launch following a Paragraph IV challenge.

Key Takeaways

• OPVEE is a 2.7 mg nalmefene hydrochloride nasal spray approved by the FDA in May 2023.
• Its excipient platform is a conventional buffered, isotonic, preserved aqueous nasal formulation.
• Benzalkonium chloride, disodium edetate, citrate buffer, sodium chloride, and water for injection are central formulation components.
• The best excipient-led opportunities are preservative-free delivery, multidose systems, heat-stable packaging, improved nasal retention, and alternative devices.
• Direct excipient substitution must address bioequivalence, nasal tolerability, microbial control, spray performance, and patent clearance.
• OPVEE’s primary commercial moat is the combination of nalmefene pharmacology, device performance, clinical data, regulatory rights, and patent protection.
• Generic entry risk is more likely to center on formulation-device integration and Orange Book-listed claims than on any single common excipient.
• The strongest commercial opportunities are differentiated lifecycle products and institutional-access versions, not simple copies of the existing formulation.

FAQs

Can benzalkonium chloride be removed from an OPVEE-like formulation?

Yes, but removal would require a new microbial-control strategy, such as a unit-dose preservative-free device or another validated preservative system. The change would require new stability, microbial, device, and clinical or bioequivalence support.

Could an OPVEE competitor use the same nalmefene dose with different excipients?

Potentially. A competitor could pursue a different buffer, preservative, chelator, or device. Freedom to operate would depend on the scope of issued claims, not on whether the alternative excipients are generally known.

Would a mucoadhesive OPVEE formulation necessarily work better?

No. Increased nasal residence time could improve retention but could also delay systemic absorption, alter spray performance, or increase irritation. Emergency reversal requires rapid and reproducible delivery.

Is OPVEE eligible for five-year new chemical entity exclusivity?

Nalmefene had prior FDA-approved injectable products, so OPVEE does not automatically qualify for five-year NCE exclusivity solely because it introduced a nasal dosage form. The applicable exclusivity must be determined from the FDA approval record and related regulatory designations.

What is the most valuable excipient innovation for public-health deployment?

A preservative-free, heat-tolerant, single-dose product with a robust low-cost actuator would likely have the strongest institutional value. It could improve stockpiling, reduce concerns over repeated nasal exposure, and simplify deployment outside clinical settings.

References

1. U.S. Food and Drug Administration. (2023). OPVEE (nalmefene hydrochloride) nasal spray prescribing information. Indivior Inc.

2. U.S. Food and Drug Administration. (2023). Drugs@FDA: OPVEE, NDA 215457. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-amendments-sometimes-referred-four-terms-1984-hatch-waxman-paragraph-four-paragraph-iv